News & Events

AGC Biologics to Expand Biopharmaceutical CDMO Capacity


Doubling the production capacity at its site in Denmark to address strong demand


(SEATTLE), November 30, 2020 -- AGC Biologics announced that it will increase the production capacity of its Copenhagen facility. AGC Biologics will construct a new building on land adjacent to its current Copenhagen site, adding production floors with 2000L single-use bioreactors, labs and office space. The total investment for this expansion is estimated to be approximately €160M, and the start of operation is scheduled for 2023.

Follow Us
Join us on LinkedIn Follow us on Twitter